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We evaluated the use of radiolabeled 4-iodo-L-meta-tyrosine as
an amino acid transport marker. The pharmacologic features of
this compound, particularly the biodistribution and excretion,
were examined by conducting in vivo and in vitro studies using
4-125I-iodo-L-meta-tyrosine (4-125I-mTyr). Results obtained for
L-14C-Tyr and 3-125I-iodo--methyl-L-tyrosine (125I-IMT) were
used for comparison. Methods: In vivo biodistribution studies
of 4-125I-mTyr were performed in male ddY mice. Urinary excre-
tion of 4-125I-mTyr and 125I-IMT with administration of probene-
cid was studied. Local distribution of 4-125I-mTyr and 125I-IMT in
kidney was visualized by autoradiography. We performed me-
tabolite analysis of 4-125I-mTyr in mice. For in vitro studies,
reabsorption mechanisms of 4-125I-mTyr were compared with
those of 125I-IMT and the parent L-14C-Tyr using superconfluent
monolayers of the porcine kidney epithelial cell line LLC-PK1 in
medium containing inhibitor (L-Tyr, D-Tyr, and 2,4-dinitrophe-
nol), in Na-free medium, and at 4°C. Results: 4-125I-mTyr
demonstrated high accumulation in the pancreas and kidney
and comparable brain uptake to that of 125I-IMT. Blood clear-
ance of 4-125I-mTyr was faster than that of 125I-IMT. Three hours
after administration, 70% of 4-125I-mTyr was excreted via the
urine, whereas 5% was found in the feces. Renal autoradiog-
raphy revealed moderate accumulation of 4-125I-mTyr and high
accumulation of 125I-IMT in the renal cortex. Probenecid further
reduced accumulation of 4-125I-mTyr and 125I-IMT in the kidney
as well as urinary excretion. At 30 min after tracer injection,
intact free 4-125I-mTyr accounted for 98.1% of the total
present in kidney and 96.3% in urine. Protein incorporation
was not observed. Uptake of 4-125I-mTyr into LLC-PK1 cell
monolayers was remarkably reduced by 5 mmol/L L-Tyr (4.6%)
and incubation at 4°C (15.6%) but was reduced by 5 mmol/L
D-Tyr (50.0%). L-14C-Tyr and 125I-IMT showed similar results;
however, uptake of 125I-IMT was enhanced by 0.1 mmol/L 2,4-
dinitrophenol (165.1%), an inhibitor of generation of energy-rich
phosphates. Conclusion: The artificial amino acid 4-125I-mTyr
demonstrated high metabolic stability, rapid blood clearance,
rapid urinary excretion, and similar biodistribution to other ra-
diolabeled L-Tyr analogs. 4-125I-mTyr can be a competitive sub-
strate of L-Tyr reabsorption. However, 4-125I-mTyr demonstrates
different pharmacologic features than those of 125I-IMT, partic-
ularly in renal handling. 4-125I-mTyr may potentially be applied
as a new amino acid transport marker.
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We recently studied the feasibility of iodinated L-meta-
tyrosine (I-L-mTyr) for measuring amino acid transport in
the brain and pancreas (1). The results indicated that I-L-
mTyr is resistant to deiodination and accumulates in the
brain. This was thought to be because the L-amino acids
penetrate the brain and the hydroxy group at position 3
increases the metabolic stability (1). According to the
method of Adams et al. (2), radioiodination of L-mTyr
results in 2 major geometric isomers, 6-iodo- and 4-iodo-L-
mTyr (6-I-mTyr, 4-I-mTyr). We separated these isomers
using high-performance liquid chromatography (HPLC) (3).
The new radiopharmaceutical 6-I-mTyr was reported to be
useful in assessing cerebral amino acid transport mecha-
nisms and quantifying metabolically active dihydroxyphe-
nylalanine (DOPA) decarboxylase (3).
In this article, we present the pharmacologic features of
the artificial amino acid 4-125I-iodo-L-meta-tyrosine (4-125I-
mTyr) (Fig. 1) (2,3). We investigated the biodistribution and
excretion and conducted metabolite analysis of 4-125I-mTyr
in mice. The renal handling of this compound was studied in
detail because most of the 4-125I-mTyr proved to be excreted
via kidney. Renal accumulation of 4-125I-mTyr and 3-125I-
iodo--methyl-L-tyrosine (125I-IMT) was visualized by au-
toradiography. Furthermore, the carrier systems related to
reabsorption of the apical membrane involved in 4-125I-
mTyr transport were examined using superconfluent mono-
layers of a porcine kidney epithelial cell line (LLC-PK1) on
plastic dishes (4,5). The results were compared with the data
for the parent Tyr and 125I-IMT. The LLC-PK1 model has
been used extensively for analyzing several functions of the
proximal tubules (6–10). In this experimental model, LLC-
PK1 forms an oriented monolayer with tight junctions on the
plastic surface and exhibits reabsorption of electrolytes and
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some nutrients via the microvilli of the apical membrane,
which are in contact with the uptake solution (5).
We also discuss the clinical perspectives of using 4-125I-
mTyr on the basis of this investigation and earlier studies
(1). To the best of our knowledge, this is the first detailed
study and pharmacologic characterization of 4-I-mTyr.
MATERIALS AND METHODS
Preparation of 4-125I-mTyr
Reagent-grade chemicals were used in this investigation (Kanto
Chemical Co., Tokyo, Japan). DL-mTyr was acquired from Sigma-
Aldrich Japan K.K. (Tokyo, Japan) and was separated by HPLC
using a chiral column (Crownpak CR(), 4  150 mm; Daicel
Chemical Industries, Tokyo, Japan). 125I-NaI was obtained from
Amersham Pharmacia Biotech U.K. (Buckinghamshire, U.K.).
The conventional chloramine-T method was used to prepare 4-125I-
mTyr, as reported (2). Chloramine-T (Sigma-Aldrich Japan) at a
concentration of 1.0 103 mol/L in 10 L 0.05 mol/L phosphate
buffer (pH 8.5) was added to a mixture of L-mTyr (100 L at 1.0
103 mol/L) and carrier-free 125I-NaI (3.7–7.4 MBq) in 35 L 0.4
mol/L phosphate buffer (pH 8.5). The resulting solution was
allowed to stand for 30 min, and 10 L of 1.0  103 mol/L
sodium metabisulfite in 0.05 mol/L phosphate buffer (pH 8.5) were
added.
Geometric isomer separation by HPLC was then performed
using a Nova-Pak C18 column (3.9  300 mm; Waters, Milford,
MA; eluent, 0.02 mol/L potassium acetate:ethanol  90:1; flow
rate, 0.5 mL/min; retention time: 4-isomer, 17–20 min; I, 4–5
min; cold mTyr, 5–7 min). Labeling efficiency and radiochemical
purity were studied using silica gel thin-layer chromatography
([TLC] catalog number Art. 5553; Merck, Darmstadt, Germany)
with 2 solvent systems, methanol:acetic acid  100:1 (Rf value:
4-125I-mTyr, 0.50; I, 0.80) and methanol:10% ammonium ace-
tate  10:1 (Rf value: 4-125I-mTyr, 0.55; I, 0.80). Solvent ex-
change was performed using saline.
As references, L-14C(U)-tyrosine (L-14C-Tyr; American Radio-
labeled Chemicals Co., St. Louis, MO), a labeled natural amino
acid, was used as the gold standard. 125I-IMT was prepared using
the method reported previously (11,12).
Biodistribution and Urinary Excretion in Mice
The ethical committees of all affiliated universities approved all
animal experiments in this study. Male ddY mice (n  5; weight,
30 g) were administered 0.1 mL 4-125I-mTyr (1.11 kBq) by injec-
tion into the tail vein. For inhibition studies, probenecid (50 mg/kg
body weight) was preadministered through the tail vein 10 min
before injection of 4-125I-mTyr (13). Urine and feces were col-
lected at various time intervals after administration. Mice were
anesthetized with ether and killed by cardiac puncture. Radioac-
tivity of urine and various organs was measured using an ARC-
1000M well-type scintillation counter (Aloka, Tokyo, Japan).
In Vivo Stability
For metabolite analysis, male ddY mice (n  5; weight, 30 g)
were injected with 0.1 mL 4-125I-mTyr (50 kBq) into the tail vein.
After 30 min, mice were anesthetized with ether and killed by
cardiac puncture. An aliquot of tissue was homogenized, and the
5% trichloroacetic acid–precipitated fraction was trapped on a
GC-50 glass filter (Advantec MFS, Inc., Dublin, CA) to facilitate
measurement of the radioactivity incorporated into the protein.
Tissue supernatant was separated by silica gel TLC (catalog num-
ber Art. 5553; Merck) using the following solvent systems: meth-
anol:acetic acid  100:1 (Rf value: 4-125I-mTyr, 0.5; I, 0.80) and
methanol:10% ammonium acetate  10:1 (Rf value: 4-125I-mTyr,
0.55; I, 0.80).
In Vivo Autoradiography
For autoradiography, 0.1 mL 4-125I-mTyr or 125I-IMT (670 kBq)
was injected into the tail vein of male ddY mice (n  4; weight,
30 g). After 5 min, mice were killed by inspiration of excess ether.
The kidney was placed in carboxymethylcellulose embedding me-
dium (Nacalai, Kyoto, Japan) and then frozen at15°C for at least
12 h. A Handex cryostat microtome (Shiraimatsu, Osaka, Japan)
was used to cut 20-mm coronal sections from posterior to anterior.
Sections were then dried at 15°C for another 24 h. Tissue slices
were left in contact with BAS-TR2040 imaging plates (Fuji Photo
Film, Kanagawa, Japan) for 24 h. Images were processed using a
BAS 2000 Bio-Imaging Analyzer (Fuji Photo Film).
In Vitro Measurement of Reabsorption
Cell line studies were performed as described by Saito et al. (5).
Briefly, LLC-PK1 cells were obtained from Dainippon Pharmaceu-
tical Co. (Osaka, Japan; catalog number 09-1392) and were cul-
tured on plastic dishes (Falcon; Becton Dickinson, Lincoln Park,
NJ) in Dulbecco’s modified Eagle’s medium (Sigma Chemical
Co., St. Louis, MO), supplemented with 10% fetal calf serum
(Equitech-Bio Inc., Ingram, TX) without antibiotics, in an atmo-
sphere of 5% CO2:95% air at 37°C. Subculturing was conducted
every 7 d using 0.02% ethylenediaminetetraacetic acid and 0.05%
trypsin. In this study, cells were used between the 220th and 235th
passages.
For uptake studies, LLC-PK1 cells were seeded on 60-mm
dishes at a cell density of 5  105 cells per dish in 5 mL complete
medium and were used on the 6th and 7th days after inoculation.
Uptake was measured in LLC-PK1 cell monolayers grown on
60-mm plastic culture dishes. The incubation medium comprised
145 mmol/L NaCl, 3 mmol/L KCl, 1 mmol/L CaCl2, 0.5 mmol/L
MgCl2, and 5 mmol/L 2-hydroxyethylpiperazine-N	-2-ethanesul-
fonic acid, with a final pH of 7.4. In the Na-dependence study,
NaCl was replaced with the same concentration of choline-Cl.
After removal of culture medium, each dish was washed once with
5 mL incubation medium for 10 min at 37°C. Cells were then
incubated with 2 mL incubation medium containing no-carrier-
added 4-125I-mTyr or L-14C-Tyr for the specified periods at 37°C,
and in the temperature dependence study, at 4°C.
For the inhibition study, L-Tyr, D-Tyr, probenecid, and 2,4-
dinitrophenol (2,4-DNP) were added to give final concentrations of
5.0 mmol/L (14), 5.0 mmol/L (14), 1 mmol/L (15), and 0.1
mmol/L (16), respectively. Cells were incubated for 5 min at 37°C
FIGURE 1. Chemical structure of 4-125I-mTyr.
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with 1.11 kBq of no-carrier-added 4-125I-mTyr or L-14C-Tyr
(American Radiolabeled Chemicals).
Thereafter, media were aspirated, and monolayers were rinsed
twice rapidly using 5 mL ice-cold incubation medium. Cells were
solubilized in 1.5 mL 1N NaOH, and the radioactivity of each
aliquot was counted. Radioactivity associated with solubilized
cells was determined using an ARC-1000M well-type scintillation
counter (Aloka) and an LS6500 liquid scintillation counter (Beck-
man Instruments, Fullerton, CA).
Statistical Analysis
Data are expressed as mean 
 SD of 3-5 measurements and
each experiment was performed in duplicate. Results were ana-




Labeling of L-mTyr yielded 4-125I-mTyr with labeling
efficiency exceeding 80%. After purification, no-carrier-
added 4-125I-mTyr with radiochemical purities exceeding
95% was obtained.
Biodistribution and Urinary Excretion in Mice
Table 1 summarizes the biodistribution of 4-125I-mTyr in
healthy mice. The observed accumulation of 4-125I-mTyr in
the pancreas was higher than that in the kidney. Accumu-
lation of 4-123I-mTyr in mouse kidney cortex was approxi-
mately 80% lower than that of 125I-IMT in terms of percent-
age injected dose/gram of tissue (%ID/g tissue) (Tables 1
and 2; Fig. 2B).
As shown in Figure 2A, rapid clearance of 4-125I-mTyr
from the blood was observed. Although the clearance of
4-125I-mTyr was faster than that of 125I-IMT in all organs
studied, organ-to-blood ratios were similar with the excep-
tion of the kidney.
Urinary excretion of 4-125I-mTyr was rapid and delayed
by probenecid administration (Fig. 3). These results dem-
onstrate that secretion of 4-125I-mTyr is competitively in-
hibited by probenecid.
In Vivo Stability
Metabolite analysis revealed that intact free amino acid
accounted for 98.11% 
 1.21% of the radioactivity in
mouse kidney and 96.29% 
 3.10% in mouse urine.
Protein incorporation of 4-125I-mTyr was not observed in
mouse kidney. Furthermore, 4-125I-mTyr displayed high sta-
bility against deiodination because free iodine comprised
only 0.17% 
 0.18% of radioactivity in the kidney and
3.50% 
 1.59% in urine.
In Vivo Autoradiography
Localization of 4-125I-mTyr and 125I-IMT in the kidney is
compared in Figure 4. At 5 min after administration, 125I-
IMT displayed substantial accumulation in the renal cortex,
whereas 4-125I-mTyr showed only moderate accumulation.
Most of the excreted 4-125I-mTyr was observed in the me-
dulla. Probenecid inhibited the cortical accumulation of
125I-IMT and 4-125I-mTyr.
In Vitro Measurement of Reabsorption
Time course analysis of 4-125I-mTyr uptake into LLC-PK1
cell monolayers shows that steady-state levels were reached
25 min after starting incubation (data not shown). An incu-
bation time of 5 min was chosen for the inhibition study.
The results of inhibition studies of 4-125I-mTyr, 125I-IMT,
and L-14C-Tyr uptake are shown in Figure 5. SignificantTABLE 1
Biodistribution of 4-125I-mTyr in Male ddY Mice
Biodistribution 5 min 15 min 30 min
Blood* 3.72 
 0.40 1.56 
 0.36 0.45 
 0.09
Brain 0.61 
 0.16 0.47 
 0.07 0.32 
 0.08
Pancreas 25.44 
 1.85 14.03 
 3.69 2.00 
 0.57
Liver 4.31 
 0.51 1.80 
 0.42 0.64 
 0.16
Stomach 1.24 
 0.22 1.05 
 0.37 2.82 
 2.27
Intestine 2.26 
 0.29 1.03 
 0.26 0.56 
 0.06
Kidney 23.77 
 4.89 12.89 
 9.53 4.24 
 1.92
Heart 2.51 
 0.33 1.42 
 0.34 0.92 
 0.36
Lung 3.76 
 0.52 1.90 
 0.41 0.74 
 0.14
Spleen 4.04 
 0.64 2.35 
 1.05 0.54 
 0.17
*%ID/mL blood (n  5 mice).
All data except blood are expressed as %ID/g tissue, mean
 1 SD.
TABLE 2
Biodistribution of 125I-IMT in Male ddY Mice
Biodistribution 5 min 15 min 30 min
Blood* 6.70 
 1.44 3.12 
 0.43 1.47 
 0.08
Brain 0.58 
 0.12 0.47 
 0.08 1.05 
 0.13
Pancreas 41.48 
 5.16 25.84 
 9.50 9.18 
 1.89
Liver 4.63 
 1.29 2.00 
 0.15 0.93 
 0.03
Stomach 4.31 
 1.66 4.81 
 1.39 2.93 
 0.28
Intestine 5.08 
 1.21 2.49 
 0.65 0.91 
 0.06
Kidney 102.62 
 0.93 75.34 
 15.74 24.05 
 6.04
Heart 5.67 
 2.16 3.10 
 0.41 1.53 
 0.08
*%ID/mL blood (n  5 mice).
All data except blood are expressed as %ID/g tissue, mean
 1 SD.
FIGURE 2. Biodistribution of 4-125I-mTyr compared with that
of 125I-IMT in mice. (A) Blood clearance. (B) Kidney radioactivity.
Each bar represents mean 
 SD of 5 animals.
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inhibition of 4-125I-mTyr uptake as well as inhibition of
125I-IMT and L-14C-Tyr uptake was noted with L-Tyr (P 
0.01). When compared with L-Tyr, D-Tyr had a smaller inhib-
itory effect on 4-125I-mTyr, 125I-IMT, and 14C-Tyr uptake.
Replacing sodium with choline slightly reduced 4-125I-mTyr
and L-14C-Tyr transport into LLC-PK1 cell monolayers.
Administration of 2,4-DNP slightly enhanced accumula-
tion of 4-125I-mTyr and L-14C-Tyr in LLC-PK1 cell mono-
layers. However, 2,4-DNP remarkably enhanced the accu-
mulation of 125I-IMT.
As seen in Figure 5, transport of 4-125I-mTyr into LLC-
PK1 cell monolayers predominantly (87%) used the Na-
independent system, with minor (13%) use of the Na-
dependent system. Incubation at 4°C significantly decreased
accumulation of 4-125I-mTyr, L-14C-Tyr, and 125I-IMT (P 
0.01). These compounds behaved similarly in inhibition
studies.
DISCUSSION
Changes in amino acid transport are frequently observed
in conditions such as cancer (17), neuropsychiatric diseases,
and substance abuse (18). Some of the tyrosine derivatives
used in positron emission CT (PET), such as O-(2-18F-
FIGURE 3. Urinary excretion of 4-125I-mTyr and effects of
probenecid administration in mice. Control compared with pro-
benecid administration. Each bar represents mean 
 SD of 5
animals. *P  0.05; **P  0.005.
FIGURE 4. Comparison of 4-125I-mTyr (A)
and 125I-IMT (B) accumulation in mouse kid-
ney with or without probenecid administra-
tion. (Left) Photograph. (Center) Superim-
posed. (Right) Autoradiograph.
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fluoroethyl)-L-tyrosine (18F-FET) and 3-18F-fluoro--methyl-
L-tyrosine (18F-FMT), and those used in SPECT, such as
123I-IMT, are reportedly transported into cells via the neutral
amino acid transport system (19–21). Of these compounds,
123I-IMT has been successfully applied clinically for brain
tumor imaging using SPECT (22); it has also been applied
as an imaging agent to study brain and pancreas function
(11,12).
In an attempt to develop a new amino acid transport
marker, we opted to use SPECT, which is widely conducted
with radioactive iodine. Because the phenol group of mTyr
provided a suitable site for labeling, direct electrophilic
radioiodination was performed for preparation of 4-125I-
mTyr. High labeling efficiency and specific activity of
4-125I-mTyr (no carrier added) can be obtained with the
chloramine-T method. Radioactive iodine has the advantage
of availability, low cost, and relatively long half-life. 4-125I-
mTyr in saline was stable for 3 wk at 4°C.
The radioiodinated compound must be resistant to rapid
breakdown by general metabolic pathways (23) because a
complicated metabolic fate of a radioiodinated compound
requires a complicated kinetic model for quantitative study.
Furthermore, stability against deiodination is essential to
prevent internal irradiation of organs that accumulate io-
dine, such as the thyroid and stomach. On the basis of the
hypothesis that position 4 of the phenol hydroxyl group
plays an important role in the substrate recognition of deio-
dinase, which reacts with 3-iodo-L-Tyr and 3,5-diiodo-L-
Tyr, we hoped to increased resistance to iodination and to
decrease renal accumulation by changing the position of the
hydroxyl group of L-Tyr without -methylation, as in 125I-
IMT. Furthermore, we hoped that 4-125I-mTyr would retain
affinity for system L transport. The results of metabolic
analysis of this study successfully demonstrated the high
metabolic stability of 4-125I-mTyr, which is comparable to
125I-IMT (21). 4-125I-mTyr was not a substrate for protein
synthesis or deiodination. In the brain, no interaction with
DOPA decarboxylase was observed during NSD-1015 in-
hibition studies (3). We believed that the hydroxy group at
position 3 and the iodine at position 4 would result in the
metabolic stability of 4-125I-mTyr (Fig. 1) (1).
Three hours after administration, 70% and 5% of
intact compound was detected in the urine and feces, re-
spectively. 4-125I-mTyr is predominantly excreted via the
urinary tract, and hepatobiliary clearance does not appear to
be substantially involved in excretion. Metabolic stability
may be 1 factor contributing to the rapid renal excretion of
the compound.
In the biodistribution study of 4-125I-mTyr (Table 1),
rapid blood clearance, maximum tissue uptake, and pro-
longed retention in the organs were found, and this is
comparable to the biodistribution of other amino acid ana-
logs, such as 18F-FET, 18F-FMT, and 123I-IMT (19–21). The
higher accumulation in the pancreas is consistent with the
characteristics of amino acid biodistribution.
The main difference between the biodistribution of 4-125I-
mTyr and 125I-IMT was the higher accumulation of 125I-IMT
in all organs studied (Tables 1 and 2). In particular, the
accumulation of 125I-IMT in kidney was about 5-fold higher
than that of 4-125I-mTyr (Fig. 2B). Another -methylated
Tyr analog, 18F-FMT, also exhibits high accumulation in the
renal cortex (24). We propose that -methylated Tyr ana-
logs possess a higher affinity for accumulative renal organic
anion secretion systems than non--methylated Tyr ana-
logs, such as 18F-FET (19) or 4-125I-mTyr. This is supported
by the fact that probenecid, which is an organic anion
secretion inhibitor in the kidney (13,25), markedly inhibits
accumulative secretion of the -methylated Tyr analog 125I-
IMT in the cortex of proximal tubule S2-like areas (Figs. 3
and 4). The actions of probenecid are largely confined to
inhibition of organic anion transport across epithelial barri-
ers (13). This is most important for the renal tubule, in
which tubular secretion of many drugs and drug metabolites
is inhibited (13). Furthermore, plasma protein binding of
FIGURE 5. Effects of inhibitors on accumulation of 4-125I-mTyr (A) L-14C(U)-Tyr (B), and 125I-IMT (C) in LLC-PK1 cell monolayers.
Each column represents mean 
 SD of 4 monolayers. *P  0.01; **P  0.05.
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both compounds was approximately 50% in our studies with
rat (data not shown). Considering the results of urinary
excretion inhibition analysis with probenecid, as shown in
Figure 3, these data seem quite reasonable on the basis of
the inhibited level of excretion. These results suggest dif-
ferent mechanisms of renal handling for 4-125I-mTyr and
125I-IMT, and -methylation could be the reason for this
difference.
The results of recent studies have raised questions as to
the nature of systems that mediate the membrane transport
of Tyr analogs, such as 125I-IMT, in cells of the renal cortex
(26). After glomerular filtration, natural amino acids gener-
ally undergo intensive reabsorption and most natural amino
acids are resorbed by S1 to S3 cells, and thus few amino
acids are excreted (27). Figure 5 illustrates 1 possible solu-
tion to the above problem. In this experimental model,
LLC-PK1 exhibits reabsorption, because LLC-PK1 com-
prises polar cells, with the apical side of monolayers con-
tacting medium and the basolateral membrane on the wall of
the culture dish (5). Figure 5 shows that reabsorption of both
4-125I-mTyr and L-Tyr was mediated by Na-independent as
well as Na-dependent systems. Decreased accumulation of
4-125I-mTyr with incubation at 4°C suggests temperature-
dependent carrier-mediated mechanisms for 4-125I-mTyr re-
absorption. Probenecid exerted no effects on 4-125I-mTyr
reabsorption.
Structural requirements for aromatic amino acid secretion
and reabsorption in canines were investigated by Williams
and Hang (28,29) using a series of Tyr analogs. It was
concluded that the L-amino acids undergo secretion and
reabsorption and that the L-configuration and amino group
are required for reabsorption, whereas ring hydroxylation
exerts little effect on resorptive transport (29). Results of
excretion studies using probenecid in mice and similar
studies in LLC-PK1 provide evidence of secretion and re-
absorption of 4-125I-mTyr. The results of our study agree
with the above reports.
Several amino acid transport systems are known to me-
diate neutral amino acid transport in the kidney. Systems B0
and B0, are Na-dependent neutral amino acid transport
systems, predominantly involved in the reabsorption of ar-
omatic amino acids in the apical membrane of proximal
tubule cells (30–32). System b0, is a Na-independent
transport system in the apical membrane of proximal tubule
cells (33). This transport system is predominantly involved
in the reabsorption of neutral and basic amino acids, includ-
ing aromatic amino acids. The majority of A and ASC,
Na-dependent neutral amino acid transport systems exist
on the basal side of the membrane (14). System L is a
Na-independent major nutrient transport system responsi-
ble for large neutral amino acids, including several essential
amino acids (34). System L is exclusively located in the
basolateral membranes (14). In addition to these transport
systems, probenecid-competitive organic anion transport
systems are believed to mediate 125I-IMT as well as 4-125I-
mTyr.
An interesting finding of this in vitro inhibition study in
LLC-PK1 is that 2,4-DNP, an inhibitor of energy-rich phos-
phate generation (26), caused a significant increase in 125I-
IMT uptake. Some of the energy-independent amino acid
transport systems that exchange intracellular amino acids
for extracellular amino acids in the apical side of the mem-
brane of the proximal tubule cells are known (30). With the
existence of an energy-dependent secretion system compris-
ing energy-independent influx of 125I-IMT and energy-de-
pendent efflux, this phenomenon is well explained. 2,4-
DNP could cause an increase in 125I-IMT uptake by
inhibiting efflux, and influx cannot be inhibited. However,
2,4-DNP caused a slight and statistically insignificant in-
crease in 4-125I-mTyr and L-14C-Tyr uptake.
Although few natural amino acids are excreted, rapid
excretion of 4-125I-mTyr and 125I-IMT via the urinary tracts
was observed. The affinity of the parent Tyr to various
transport systems, and metabolic pathways, may be changed
by altering the structural heterogeneity of artificial amino
acids through -methylation and iodination of the benzene
ring.
These results indicate several potential clinical applica-
tions 4-125I-mTyr. In the biodistribution study, brain uptake
of 4-125I-mTyr was comparable to that of 125I-IMT, suggest-
ing the possibility of brain function imaging. A possible use
in pancreas imaging was also indicated because of the
relatively high uptake. The properties of 4-125I-mTyr, in-
cluding rapid clearance from blood, rapid urinary excretion,
and relatively low accumulation in kidney, offer advantages
for performing abdominal tumor SPECT of areas around the
kidney when compared with -methylated Tyr analogs. A
prerequisite for an improved amino acid, such as 4-125I-
mTyr, must be that tumor uptake is at least as high but
preferably higher than that of 123I-IMT. Further investiga-
tion is needed to clarify these points and to develop 4-125I-
mTyr as an amino acid transport marker for SPECT.
CONCLUSION
The artificial amino acid 4-125I-mTyr demonstrated high
metabolic stability, rapid blood clearance, rapid urinary
excretion, and biodistribution similar to that of 125I-IMT.
We believe that 4-125I-mTyr is a competitive substrate of
L-Tyr reabsorption. However, 4-125I-mTyr possesses differ-
ent pharmacologic features than 125I-IMT, particularly in
renal handling. 4-125I-mTyr may potentially be applied as a
new amino acid transport marker. Further investigation is
needed to develop 4-125I-mTyr as an amino acid transport
marker for SPECT and to clarify its behavior in each target
organ and tissue.
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